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Abstract
The androgen receptor (AR) mediates the growth of benign and malignant prostate in response to
dihydrotestosterone (DHT). In patients undergoing androgen deprivation therapy for prostate
cancer, AR drives prostate cancer growth despite low circulating levels of testicular androgen and
normal levels of adrenal androgen. In this report we demonstrate the extent of AR transactivation
in the presence of 5α-androstane-3α,17β-diol (androstanediol) in prostate-derived cell lines
parallels the bioconversion of androstanediol to DHT. AR transactivation in the presence of
androstanediol in prostate cancer cell lines correlated mainly with mRNA and protein levels of
17β-hydroxysteroid dehydrogenase 6 (17β-HSD6), one of several enzymes required for the
interconversion of androstanediol to DHT and the inactive metabolite, androsterone. Levels of
retinol dehydrogenase 5, and dehydrogenase/reductase short-chain dehydrogenase/reductase
family member 9, which also convert androstanediol to DHT, were lower than 17β-HSD6 in
prostate-derived cell lines, and higher in the castration-recurrent human prostate cancer xenograft.
Measurements of tissue androstanediol using mass spectrometry demonstrated androstanediol
metabolism to DHT and androsterone. Administration of androstanediol dipropionate to
castration-recurrent CWR22R tumor bearing athymic castrated male mice produced a 28-fold
increase in intratumoral DHT levels. AR transactivation in prostate cancer cells in the presence of
androstanediol resulted from the cell-specific conversion of androstanediol to DHT, and
androstanediol increased LAPC-4 cell growth. The ability to convert androstanediol to DHT
provides a mechanism for optimal utilization of androgen precursors and catabolites for DHT
synthesis.
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INTRODUCTION
Prostate cancer development and growth depend on the androgen receptor (AR), a ligand-
dependent transcription factor required for normal male reproductive function. AR binds
testosterone and dihydrotestosterone (DHT) with high affinity to mediate androgen-
dependent gene transcription (1). AR is expressed during all stages of prostate cancer
progression, and increased AR transcriptional activity is a hallmark of the disease. Inhibition
of prostate cancer cell growth by small inhibitory RNAs that target AR provides further
evidence for obligatory AR function in prostate cancer development and progression (2).
Prostate cancer growth is stimulated initially by circulating testicular androgens. After
treatment by medical or surgical castration, prostate cancers adapt to the androgen-deprived
environment to maximize AR function through mechanisms facilitated by the genetic
instability of cancer cells. Mechanisms for increased AR transactivation during prostate
cancer progression to castration-recurrent growth include AR gene amplification (3),
somatic AR gene mutations that provide a gain-of-function by decreasing AR ligand
specificity (4,5), and increased AR interactions with coregulators whose levels also increase
during prostate cancer progression (6,7). Prostate cancer tissue production of androgen
develops during androgen deprivation therapy (8–10), and increased mitogen signaling and
AR phosphorylation influences AR transcriptional activity (6,11).
The present study investigated whether AR activation by the conversion of 5α-
androstane-3α,17β-diol (androstanediol) to DHT contributes to prostate cancer growth when
circulating testicular androgen levels are low. Cell-specific bioactivation of androstanediol
to DHT and catabolism to androsterone were investigated as mechanisms for increased AR
transcriptional activity that mediates castration-recurrent growth in men undergoing
androgen deprivation therapy to treat advanced prostate cancer. Levels of bioavailable DHT
reflect activities of several metabolic enzymes. Intracellular DHT derives primarily from the
irreversible conversion of testosterone by 5α-reductase. Androstenedione and
dehydroepiandrosterone sulfate are major circulating adrenal androgens converted to
androstanediol and DHT in human prostate (12). Androstanediol is an inactive DHT
metabolite that can be reversibly oxidized to DHT.
Herein we demonstrate AR transcriptional activity in prostate cancer cell lines in the
presence of androstanediol is related directly to mRNA and protein levels of 17β-
hydroxysteroid dehydrogenase 6 (17β-HSD6) to a greater extent than the retinol
dehydrogenase 5 (RDH5), or dehydrogenase/reductase short-chain dehydrogenase/reductase
family member 9 (DHRS9), enzymes that convert androstanediol to DHT. Results were
corroborated using mass spectrometry to measure DHT and androsterone levels in cells after
incubation with androstanediol, and after the administration of androstanediol dipropionate
to athymic mice bearing the CWR22R castration-recurrent prostate cancer xenograft.
Androstanediol was converted to DHT in the CWR22R xenograft tumor, where mRNA
levels were measured for 17β-HSD6, DHRS9 and RDH5. The results support the notion that
androstanediol metabolism to DHT coupled with 5α-reductase activity contributes to
optimal utilization of androgen precursors and catabolites for AR transactivation during
prostate cancer development and progression.
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Human and mouse tissues
Patient specimens of androgen-stimulated benign prostate and androgen-stimulated and
castration-recurrent prostate cancer correspond to samples analyzed for AR and melanoma
antigen gene protein-A11 mRNA expression (7). Procedures using mice were performed in
accordance with the National Institutes of Health and Roswell Park Cancer Institute
Institutional Animal Care and Use Committee and Institutional Biosafety Committee.
Serially transplanted androgen-dependent CWR22 human prostate cancer xenografts were
propagated in athymic nu/nu mice (13) and excised before and at different times after
castration for RNA analysis using quantitative real-time PCR (7). To demonstrate
intratumoral conversion of androstanediol to DHT, male athymic nude mice 4 to 5 weeks
old were purchased from Harlan Sprague Dawley, Inc. (Indianapolis, IN) and housed
individually in the Division of Laboratory Animal Research Facility, Roswell Park Cancer
Institute. One day after castration, mice were inoculated subcutaneously on one flank with
106 CWR22R castration-recurrent xenograft cells suspended in Matrigel (1:1 mixture, BD
Biosciences, Bedford, MA). When CWR22R tumors measured 0.5 cm3, 7 mice were
injected subcutaneously at the tumor site with 1 mg androstanediol dipropionate (Steraloids,
Newport, RI) in 0.1 mL sesame oil, and 5 mice received vehicle alone. Tumors were excised
2 days later, cut into 0.1 cm3 pieces, frozen in liquid N2 and stored at −80°C until analysis
using mass spectrometry.
Cell culture, DNA transfection and immunoblot analysis
For AR transcription assays, cells were cultured as described (1,7). CWR-R1 (2 × 105 cells/
well of 12 well plates), RWPE-2 (1.5 × 105), LAPC-4 (2 × 105), LNCaP (3.5 × 105),
LNCaP-C4-2 (2 × 105) and DU145 cells (1.5 × 105) were transfected using Effectene
(Qiagen) with 0.01 µg pCMV-AR and 0.1 µg (CWR-R1 and LAPC-4) or 0.25 µg (RWPE-2,
LNCaP, LNCaP-C4-2 and DU145) prostate-specific antigen enhancer luciferase reporter
(PSA-Enh-Luc). PWR-1E (2 × 105), PC-3 (1.5 × 105) and HeLa cells (5 × 104) were
transfected in 12 well plates using FuGENE 6 (Roche Applied Science) with 0.01 µg
pCMV-AR and 0.25 µg PSA-Enh-Luc. CV1 cells (4.2 × 105 cells/6 cm dish) were
transfected using calcium phosphate with 0.1 µg pCMV-AR and 5 µg PSA-Enh-Luc. Cells
were transferred to serum-free phenol red-free medium 24 h after transfection, and incubated
for 24 h with and without testosterone, DHT and androstanediol (Sigma). Cells were washed
with phosphate buffered saline and harvested in 0.25 mL (or 0.5 mL for CV1 cells) lysis
buffer containing 1% Triton X-100, 2 mM EDTA and 25 mM Tris phosphate, pH 7.8. After
rocking for 30 min at room temperature, 0.1 mL aliquots were assayed for luciferase activity
using an automated Lumistar Galaxy (BMG Labtech) luminometer.
Immunoblots were performed by plating cells in 10 cm dishes with serum-containing
medium to achieve 40 to 60% confluence the next day. After 48 h, cells were scraped into
cold phosphate buffered saline, extracted in 0.1 to 0.2 mL lysis buffer containing 1% Triton
X-100, 1% deoxycholate, 0.1% SDS, 0.15 M NaCl, 2 mM EDTA, 2 mM sodium vanadate,
0.05 M sodium fluoride, 50 mM Tris-HCl, pH 8.0 and 0.1 µM DHT, and 150 µg protein/
lane analyzed on 12% acrylamide gels containing SDS. Nitrocellulose transfer blots were
probed using AR52 (10 µg/mL) and AR32 (0.3 µg/mL) antibodies, and HSD17B6 rabbit
polyclonal antibody (Abcam ab62221, 1.25 µg/mL). To probe β-actin using a mouse
antibody (Abcam, 1:1000 dilution), blots stored at 4°C were stripped at 55°C for 25 min in
buffer containing 2% SDS, 92 mM β-mercaptoethanol and 62.5 mM Tris-HCl, pH 6.7. The
blot was washed twice for 10 min with 0.15 M NaCl, 0.05% Tween 20 and 10 mM Tris-
HCl, pH 7.5, and blocked for 1 h in the same buffer containing 5% nonfat dry milk prior to
antibody addition. Immunoreactive bands were visualized by chemiluminescence
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(SuperSignal Western Dura Extended Duration substrate, Pierce Biotechnology, Inc.,
Rockford Ill).
LAPC-4 cell growth assays were performed in triplicate by plating 4 × 104 cells/well of 24
well plates in RPMI-1640 medium containing 10% charcoal stripped fetal bovine serum
(Atlanta Biologicals), 20 mM L-glutamine, penicillin and streptomycin. The next day and 48
h later, 0.1 ml serum-free medium was added/well to a final concentration of 0.1 nM DHT
and 10 nM androstanediol. Twenty-four h after hormone addition (day 1) and at 24 h
intervals, media were aspirated, 0.2 ml fresh serum-free medium and 20 µl WST-8 cell
counting reagent (Dojindo Molecular Technologies) were added/well. Cells were incubated
for 2.5 h at 37°C and optical density determined at 485 nm. Statistical analysis was
performed using the Pearson Product Moment Correlation.
Real-time reverse transcription-PCR
RNA was extracted using TRIzol Reagent (Invitrogen). First strand complementary DNA
(cDNA) was prepared using SuperScript II reverse transcriptase (Invitrogen). PCR primers
and fluorogenic probe for the constitutive housekeeping gene, peptidylprolyl isomerase A
(cyclophilin A) were described (14). Primers and probe for human retinol dehydrogenase 5
(RDH5) (Hs00161263-m1, Applied Biosystems) yield a 126 base pair amplicon spanning
exon 3 and 4 junction at assay location nucleotide 681 (NM-002905.2). The 17β-HSD6
primers and probe (Hs00366258-m1, Applied Biosytems) yield a 84 base pair amplicon
spanning exon 3 and 4 junction at assay location 679 nucleotides (NM-003725.2). Human
DHRS9 primers and probe (Hs00608375-m1, Applied Biosytems) result in a 66 base pair
amplicon spanning exon 3 and 4 junction at assay location nucleotide 872 (NM-199204.1).
PCR reactions (20 µL) contained cDNA prepared from 0.04 µg total RNA for 17β-HSD6
and RDH5 mRNA, and 0.4 µg total RNA for DHRS9 and peptidylprolyl isomerase A.
cDNA was combined with 4 µL Light Cycler TaqMan Master mix (Roche) and 0.5 µL 20X
TaqMan Mix (Applied Biosystems). Thermal cycler reactions were performed in triplicate
and repeated twice using a Roche LightCycler at 95°C for 10 min, followed by 55 cycles at
95°C for 15 sec, 60°C for 25 sec and 72°C for 1 sec. mRNA copy number was calculated
based on CT value of 21.85 for 4 × 105 copies with an amplification efficiency of 2
normalized by total RNA in the reaction.
Liquid chromatography tandem mass spectrometry
Liquid chromatography tandem mass spectrometry analysis of DHT, androstanediol and
androsterone was performed as described (9). Cells were incubated for 48 h at 37°C with
100 nM androstanediol in serum-free, phenol red-free medium. Cells and media were
collected together in triplicate and data pooled from two experiments. Deuterated 5α-
androstan-17β-ol-3-one-16,16,17-d3 (DHT-d3) (CDN Isotopes, Pointe-Claire, Quebec,
Canada) (12 ng) was added as internal standard and samples were extracted twice with 1.5
mL 9:1 chloroform:acetone. Organic layers were combined, evaporated under vacuum and
concentrated using solid phase extraction carbon-18 columns (Varian, Palo Alto, CA). DHT,
androstanediol and androsterone were measured using an Agilent 1100 capillary liquid
chromatography system (Palo Alto, CA) coupled to an Applied Biosystems–MDS Sciex
API-3000 triple quadrupole mass spectrometer (MDS Sciex, Concord, ON, Canada).
Positive ions were formed via dopant-assisted atmospheric pressure photoionization
(Applied Biosystems, Foster City, CA). A Phenomenex Luna C18 column (3 µm, 150×0.5
mm) and a gradient profile using mobile phase A (2 mM ammonium formate) and mobile
phase B (2 mM ammonium formate in methanol) at 175 µL/min (65% to 80% at 2.25 min
and 95% at 13 min) were used at 60°C. Androgen parent-product ion pairs monitored (mass
to charge ratio, m/z) were 305.2 to 255.2 for DHT, 273.2 to 255.2 for androstanediol, 291.2
to 273.2 for androsterone, and 308.2 to 258.2 for the DHT-d3 internal standard. DHT,
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androstanediol and androsterone standards were from Sigma-Aldrich (St. Louis, MO). DHT-
d3 deuterated twice at carbon 16 and once at carbon 17 was used to quantitate androgen.
Steroid concentrations were calculated based on pmol/g assuming 1000 g/L. The 10 pg limit
of detection for DHT had signal to noise ratio >3, and the 50 pg limit of quantitation of DHT
had signal to noise ratio >10.
RESULTS
Cell-specific AR transactivation in the presence of androstanediol
AR transactivation in the presence of testosterone, DHT or androstanediol was compared in
benign and cancer-derived cell lines that included monkey kidney CV1 cells, human cervical
carcinoma HeLa cells, benign human prostate-derived PWR-1E cells, and PC-3, LAPC-4
and CWR-R1 human prostate cancer cells (Fig. 1). A concentration-dependent increase in
AR transcriptional activity was demonstrated in response to testosterone and DHT in all cell
types subsequent to transfection of pCMV-AR and the PSA-Enh-Luc reporter gene. The
minimal transactivation of the PSA enhancer after transfection with pCMV5 empty vector
showed that androgen-dependent gene activation resulted from the expressed wild-type AR,
with maximal luciferase activity between 0.1 to 10 nM testosterone or DHT. CWR-R1 and
LAPC-4 cells appeared more responsive to low levels of testosterone and DHT (Fig. 1F).
In contrast to testosterone and DHT, there were major cell-type differences in AR
transactivation with androstanediol. AR transactivation in the presence of 10 nM
androstanediol was insignificant in CV1 cells, but evident in HeLa cells at 10 nM
androstanediol (Figs. 1A and B). In PC-3, LAPC-4, CWR-R1 and PWR-1E cells,
androstanediol was nearly equipotent with testosterone and DHT (Fig. 1C–F). AR binds
androstanediol with low affinity (15), suggesting AR transactivation with androstanediol
resulted from cell-specific conversion to DHT.
To investigate whether cell-specific AR transactivation in the presence of androstanediol
resulted from oxidative conversion to DHT, different cell types were incubated with 100 nM
androstanediol and androgen metabolites measured using mass spectrometry (Fig. 2A). Cell
incubations were performed for 24 h to parallel the AR transactivation assays (Fig. 1) and
for 48 h to assess metabolite stability. Low to undetectable androstanediol was measured in
all cell types after 24 and 48 h (Fig. 2A). In contrast, DHT was highest in PWR-1E cells, at
moderate levels in the LAPC-4, CWR-R1 and PC-3 cells, but nearly undetectable in HeLa
and CV1 cells. Testosterone was undetectable (LAPC-4, PC-3 and HeLa cells) or 5-fold less
than DHT (CWR-R1 cells) (not shown). Highest levels of androsterone were measured in
HeLa and CV1 cells, with lower levels of androsterone in prostate-derived cells in an
inverse relationship with DHT. For LNCaP and LNCaP-C4-2 cells, mass spectrometry
indicated essentially undetectable levels of androstanediol, DHT, androsterone, testosterone
and 5α-androstenedione after 24 and 48 h incubations with 100 nM androstanediol,
consistent with the inability of androstanediol to activate AR in LNCaP cells (not shown),
and with the high glucuronosyltransferase activity in LNCaP cells, an enzyme that
irreversibly converts androstanediol to the sugar conjugate for excretion (16).
An additional indicator of androstanediol conversion to an active androgen was provided by
the ability of 10 nM androstanediol or 0.1 nM DHT to increase the growth of LAPC-4 cells
(p < 0.001) that contain a wild-type AR (Fig. 2B). Together the results indicate cell-specific
AR transcriptional activity and prostate cancer cell growth in the presence of androstanediol
results from the oxidative metabolism of androstanediol to DHT.
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Cell-specific metabolism of androstanediol
Several enzymes are involved in the oxidative metabolism of androstanediol to DHT, and in
the reductive conversion of androstanediol to androsterone (Fig. 3). Androstanediol is
converted to DHT by oxidative 3α-HSD activity of 17β-HSD6 (17), RDH5 (18) and DHRS9
(19) (Table 1). Androstanediol is metabolized to androsterone by 17β-HSD6 and 11, and
androsterone is glucuronidated for excretion (20–22).
Quantitative RT-PCR analysis of RNA from different cell types indicated higher levels of
17β-HSD6 mRNA in prostate-derived cells than DHRS9 or RDH5 mRNA (Fig. 4A), which
correlated directly with AR transactivation and DHT levels after incubation with
androstanediol (Figs. 1 and 2A). 17β-HSD6 mRNA levels were lowest in CV1 cells, where
AR was transcriptionally inactive with androstanediol. HeLa cell 17β-HSD6 mRNA levels
were ~7-fold greater, consistent with the increase in AR activity with 10 nM androstanediol.
Highest levels of 17β-HSD6 mRNA were in PWR-1E and RWPE-2 benign prostate cells,
and in LNCaP, LNCaP-C4-2, CWR-R1 and DU145 prostate cancer cells, where AR
transactivation with androstanediol was similar to testosterone or DHT. In contrast, DHRS9
and RDH5 mRNA levels were lower than 17β-HSD6 mRNA (Fig. 4A) and did not correlate
with DHT levels or AR transactivation with androstanediol. RDH5 mRNA levels were ~4-
fold higher in CWR-R1 cells than other cell types. However, this increase was not
associated with a shift in dose response of AR activity with androstanediol relative to other
prostate cancer cells (Fig. 1).
Higher levels of 17β-HSD6 mRNA in prostate-derived cell lines where AR activity was
greatest in response to androstanediol were also associated with higher levels of 17β-HSD6
protein (Fig. 4B). The ~30 kDa 17β-HSD6 protein was detected in all prostate-derived cell
lines, but not in CV1 or HeLa cells which had correspondingly lower levels of 17β-HSD6
mRNA and AR was less active with androstanediol. AR protein levels were higher in
LAPC-4, CWR-R1 and LNCaP prostate cancer cells than in PC-3, PWR-1E, HeLa or CV1
cells (Fig. 4B). Longer exposure of the transblot revealed low levels of 17β-HSD6 in HeLa
cells and AR in PWR-1E cells (not shown). However, 17β-HSD6 siRNA introduced into
cells did not decrease AR transactivation in response to androstanediol due to insufficient
knockdown and the contributions of other enzymes that metabolize androstanediol to DHT.
The results suggest that 17β-HSD6 contributes to androstanediol conversion to DHT in
benign and malignant prostate, and bioactivation of androstanediol to DHT accounts for AR
transactivation in the presence of androstanediol.
Androgen metabolism during prostate cancer progression
To investigate whether enzymes involved in DHT biosynthesis in prostate cancer tissue
contribute to prostate cancer progression during androgen deprivation therapy, mRNA levels
for 17β-HSD6, DHRS9 and RDH5 were determined in the CWR22 xenograft at different
times after castration. The CWR22 human prostate cancer xenograft undergoes remission
after castration and regrowth ~120 days after castration and thus mimics the clinical
response to androgen deprivation (23,24). 17β-HSD6, DHRS9 and RDH5 mRNA levels
varied in the CWR22 xenograft depending upon time after castration (Fig. 5A). 17β-HSD6
mRNA levels decreased ~5-fold within 2 days after castration and remained low throughout
castration-recurrent tumor growth. DHRS9 and RDH5 mRNA levels increased transiently
after castration, but were unchanged in the castration-recurrent xenograft CWR22 tumor
relative to the tumor prior to castration.
The decline in 17β-HSD6 mRNA after castration in the CWR22 xenograft was investigated
further using androgen-stimulated benign prostate and androgen-stimulated and castration-
recurrent prostate cancer tissue. Similar to results with the CWR22 prostate cancer
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xenograft, 17β-HSD6 mRNA levels were highest in benign prostate, more variable in
androgen-stimulated prostate cancer, and declined ~10-fold in most specimens of castration-
recurrent prostate cancer (Fig. 5B).
In vivo metabolism of androstanediol to DHT
To obtain further evidence for the in vivo intratumoral metabolism of androstanediol to
DHT, castrated CWR22R-bearing athymic mice were injected subcutaneously in oil at the
tumor site with 1 mg androstanediol dipropionate. Intratumoral DHT measured 48 h later
using tandem mass spectrometry (Table 2) was 28-fold higher (28.1 ± 6.2 nM DHT) after
administering androstanediol dipropionate than control tumor-bearing mice injected with
vehicle (1.0 ± 0.7 nM DHT). Androsterone levels increased 4.3-fold after injection of
androstanediol dipropionate. Androstanediol was not detected in control or treated animals,
consistent with its metabolism to DHT and androsterone. The results demonstrate
intraprostatic tumoral metabolism of androstanediol to DHT may contribute to AR
transactivation and prostate cancer progression.
DISCUSSION
Androstanediol as an active androgen precursor
The metabolic processes that contribute to castration-recurrent prostate cancer appear to be
diverse, as reflected by an apparent wide variation in mechanisms and tissue androgen
levels. On the other hand, AR continues to be a focus for new drug development to achieve
sustained inhibition or eradication of prostate cancer growth during prolonged androgen
deprivation therapy. AR activity depends on high affinity binding of testosterone or DHT,
whose steady state levels are regulated by a family of reductive and oxidative enzymes
(Table 1). The major circulating androgen testosterone synthesized in the testis from 4-
androsten-3,17-dione (androstenedione) by reductive 17β-HSD (25) (Fig. 3,Table 1) is
irreversibly converted to DHT by type 2 steroid 5α-reductase (20) that also converts
androstenedione, a major adrenal androgen, to 5α-androstane-3,17-dione. Androstanedione
is reversibly converted to DHT by 17β-HSD, or indirectly through androsterone and
androstanediol (26). DHT is reversibly inactivated by conversion to androstanediol by
reductive 3α-HSD activity (21,27) of type 3 3α-HSD aldo-keto reductase 1C2 (AKR1C2)
that functions as both 3- and 17-ketosteroid reductase (19,28–30). The 17β-HSD activity of
AKR1C3 converts androstanediol to androsterone, and androstenedione to testosterone
(28,31). Increased levels of AKR1C ketosteroid reductases were associated with castration-
recurrent prostate cancer (32). Androstanediol is metabolized by oxidative 17β-HSD activity
of 17β-HSD6 and 17β-HSD11 to androsterone, which is glucuronidated and excreted (20–
22).
In some prostate cancers, gain-of-function AR mutations may account for androstanediol
activation of AR and increased cell growth (4,33). However, most prostate cancers retain
wild-type AR that is transcriptionally inactive when bound to androstanediol (15).
Alternative mechanisms for prostate cancer tissue DHT production during androgen
deprivation therapy are supported by the lower levels of DHT in prostate after treatment
with the type 2 5α-reductase inhibitor, finasteride (34), although some evidence suggests an
increase in 5α-reductase type 1 activity (35). Treatment with the dual type 1 and type 2 5α-
reductase inhibitor dutasteride decreased prostate tissue DHT from 11.5 to 0.8 nM, with a
compensatory increase from 0.2 to 11.8 nM testosterone (36).
The biological significance of the back conversion of androstanediol to DHT is supported by
androstanediol-induced prostate growth in beagle dogs (37), conversion of androstanediol to
DHT in humans (38), and androstanediol-induced masculinization of the tammar wallaby
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(39,40). Conversion of androstanediol to DHT has been attributed to several oxidative 3α-
HSD enzymes. These enzymes include retinol dehydrogenase 4 (RoDH4) and RDH5 (18),
17β-HSD6 (18,19) and 10 (54) and DHRS9 (19,42) (Table 1). These hydroxysteroid
dehydrogenases oxidize or reduce the 3 or 17 ketone group of androgens, with a preference
for oxidization of the 3 ketone that contributes to androstanediol oxidation to androsterone.
17β-HSD6 functions primarily as a 3α-hydroxysteroid oxidoreductase that converts
androstanediol to DHT, and lacks stereospecificity in the reductive direction (17). 17β-
HSD6 is expressed predominantly in stromal cells at higher levels than RoDH4 or RDH5,
and is considered a predominant enzyme in androstanediol conversion to DHT in human
prostate (19,29). A mitochondrial 17β-HSD10 converts androstanediol to DHT in prostate
tissue (Table 1) (43). Androstanediol also is acted upon by glucuronosyltransferase for rapid
excretion of androstanediol glucuronide as observed in LNCaP cells (16).
Our studies have shown that benign prostate and prostate cancer cells metabolize
androstanediol to DHT. Administration of androstanediol dipropionate at the CWR22R
tumor site caused a 28-fold increase in DHT. Androstanediol also promoted the androgen-
dependent growth of LAPC-4 cells. Since androstanediol was nearly equipotent with DHT
in AR transcriptional activation in most of the prostate cell lines, the results indicate that
conversion of androstanediol to DHT was sufficient to activate AR.
Conversion of androstanediol to DHT by 17β-HSD6
Higher levels of DHT and lower levels of androsterone correlated in most cell lines with
greater AR transactivation in the presence of androstanediol. Quantitative mRNA
measurements and enzyme protein levels suggested 17β-HSD6 is a predominant
multifunctional enzyme in the oxidation and reduction of 3 and 17 keto groups, and levels
correlated directly with the extent of androstanediol back-conversion to DHT and AR
transactivation in the presence of androstanediol.
The ability of benign and malignant prostate cells to convert androstanediol to DHT
provides a mechanism for increased AR transactivation in response to adrenal-derived
androgen precursors (39). De novo synthesis of DHT from progesterone is an alternative
pathway involved in environmental androgen production (44) and in castration-recurrent
prostate cancer (10). During androgen deprivation therapy, androstenedione is a major
circulating adrenal androgen converted to DHT through testosterone. Androstanediol is not a
major adrenal androgen. However, 5α-reductase type 1 is expressed in rat adrenal and levels
increased after androgen withdrawal (45). This raises the possibility that 5α-reductase type 1
can convert adrenal 17α-hydroxyprogesterone to 17α-hydroxy-dihydroprogesterone, an
androstanediol precursor (46). Adrenal androstanediol also may derive from the metabolism
of androstenedione to androstanedione by 5α-reductase type 1, the conversion of
androstanedione to androsterone, and androsterone to androstanediol by AKR1C3 (32).
Increased availability of adrenal androstanediol in patients undergoing androgen deprivation
therapy could provide the substrate necessary for conversion of androstanediol to DHT by
17β-HSD6.
Enzyme activity depends ultimately on mRNA and protein levels. Measurements of 17β-
HSD6 mRNA and protein levels in prostate cancer cell lines correlated well with AR
transactivation in response to androstanediol, and with the conversion of androstanediol to
DHT based on mass spectrometry measurements. However, hydroxysteroid dehydrogenase
activities also depend on the levels of oxidized and reduced NAD/H and NADP/H (43).
Our studies suggest that 17β-HSD6 is one of several enzymes involved in the peripheral
conversion of androstanediol to DHT in prostate. 17β-HSD6 mRNA levels declined 5 to 10-
fold in the castration-recurrent CWR22 and clinical specimens compared to androgen-
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stimulated prostate cancer, and did not rebound with castration-recurrent tumor growth. The
decline in 17β-HSD6 mRNA in prostate cancer tissue after castration is consistent with the ~
90% decline in DHT to levels that remain sufficient to activate AR (8,9). DHT levels may
also decrease because of less 5α-reduction (35). In contrast, DHRS9 and RDH5 mRNA
levels increased transiently after castration in the CWR22 tumor, but were similar in the
androgen-stimulated and castration-recurrent CWR22 xenografts. The results contrast with a
recent report that suggested a slight increase in RDH5 mRNA levels in the LNCaP xenograft
upon progression to castration-recurrent growth (10).
Unlike DHT, testosterone persists in the normal range in castration-recurrent prostate cancer
tissue (8,9) from local tissue production and from adrenal androgen conversion such as from
dehydroepiandrosterone in stromal cells (47). Testosterone may serve a greater role in AR
transactivation in castration-recurrent prostate cancer growth through mechanisms that
include increased levels of AR coactivators (6,7) and, in uncommon cases, AR somatic
mutants such as AR-H874Y that increase testosterone-dependent AR transcriptional activity
to levels similar to DHT (1,48). However, our studies suggest that testosterone was not a
major metabolite of androstanediol metabolism to DHT.
Clinical relevance and conclusions
The importance of local active androgen production in prostate cancer growth during
androgen deprivation therapy has gained renewed attention. Prostate tissue DHT persists
after castration at levels approximately 10% of normal, with higher levels of testosterone (8–
10,49–51). Steroid 5α-reductase levels increase in androgen-stimulated benign prostate and
prostate cancer (52), and a shift from steroid 5α-reductase type 2 toward type 1 contributes
to the conversion of testosterone to DHT in prostate cancer (35). The prevalence of prostate
cancer progression during androgen deprivation therapy by medical or surgical castration
suggests mechanisms independent of AR may contribute to prostate cancer growth.
However, inhibition of prostate cancer growth by reducing AR levels indicates that AR is a
critical mediator of castration-recurrent growth (2). In agreement with these findings, a
phase I clinical trial using abiraterone acetate, a selective steroid 17α-hydroxylase (CPY17)
inhibitor, reduced PSA levels (53), which suggests that ligand-activated AR contributes to
castration-recurrent prostate cancer growth. We have shown that prostate-derived cells and
tissues express steroid metabolic enzymes important in DHT synthesis that maintain AR-
dependent gene transcription to a greater extent than in cells from other organs. AR may be
transcriptionally active in castration-recurrent prostate cancer through local bioactivation of
androstanediol to DHT by 17β-HSD6. The acquired capacity of prostate cancer cells to
produce testosterone and DHT from androgen precursors and catabolites establishes an
environment for AR stimulation of recurrent growth during androgen deprivation therapy.
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Figure 1. Cell-specific wild-type AR transactivation in the presence of androstanediol
(A) CV1, (B) HeLa, (C) PWR-1E, (D) PC-3, (E) LAPC-4 and (F) CWR-R1 cells were
transfected as described in Methods with pCMV5 empty vector (p5) or pCMV-AR and
PSA-Enh-Luc and incubated for 24 h in serum-free, phenol red-free medium in the absence
and presence of increasing concentrations of testosterone (T), DHT and androstanediol
(Diol). Luciferase activity measurements indicating the mean ± S.E. are representative of at
least three independent experiments.
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Figure 2. Androstanediol metabolism to DHT increases LAPC-4 cell growth
(A) PWR-1E (PW), LAPC-4 (LA), CWR-R1 (CW), PC-3 (PC), HeLa (HL), and CV1 (CV)
cells were incubated in serum-free, phenol red-free medium containing 100 nM
androstanediol for 24 and 48 h at 37°C. Steroids were extracted from cells and medium and
quantitated using mass spectrometry. Shown are the nM concentrations of androstanediol
(Diol), DHT and androsterone. (B) LAPC-4 cell growth assays were performed as described
in Methods. Cells were incubated without hormone (- -) or with 0.1 nM DHT (O) or 10 nM
androstanediol (▲). Assays performed in triplicate are the mean ± SE of duplicate
experiments.
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Figure 3. Schematic diagram of DHT metabolism
Androstenedione is metabolized to testosterone in peripheral tissues by aldo-keto reductase
1C3 (AKR1C3). 5α-reductase type 2 irreversibly converts testosterone to DHT which is 3-
keto reduced reversibly to the inactive metabolite androstanediol by the aldo-keto reductase
1C2 (AKR1C2). Androstanediol is oxidized to DHT by 17β-hydroxysteroid dehydrogenase
6 (17β-HSD6), retinol dehydrogenase 5 (RDH5) and dehydrogenase/reductase short-chain
dehydrogenase/reductase family member 9 (DHRS9). Androstanediol is oxidized reversibly
to androsterone by 17β-HSD6 and 11.
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Figure 4. Cell-specific expression of 17β-HSD6, DHRS9 and RDH5 mRNA and 17β-HSD6
protein expression in different cell lines
(A) RNA was analyzed by quantitative RT-PCR from LNCaP (LN), LNCaP-C4-2 (C4),
CWR-R1 (CW), LAPC-4 (LA), PC-3 (PC), DU145 (DU), PWR-1E (PW), RWPE-2 (RW),
HeLa (HL) and CV1 cells (CV) for 17β-HSD6, DHRS9 and RDH5. (B) Cell extracts (150
µg protein/lane) were analyzed on immunoblots for CV1 (CV), HeLa (HL), PWR-1E (PW),
PC-3 (PC), LAPC-4 (LA), CWR-R1 (CW) and LNCaP (LN) cells. The upper panel was
probed with AR32 and AR52 antibodies, and the lower portion with 17β-HSD6 rabbit
polyclonal antibody, and stripped and reprobed with mouse β-actin antibody.
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Figure 5. 17β-HSD6, DHRS9 and RDH5 mRNA levels in the CWR22 xenograft before and after
castration and 17β-HSD6 mRNA levels in benign and malignant prostate
(A) RNA was extracted from CWR22 tumors before castration (0) and 2, 8, 12 and 120 days
after castration, and from the castration-recurrent tumor > 120 days after castration (R).
mRNA was measured using quantitative PCR for 17β-HSD6, DHRS9 and RDH5 and
expressed as mRNA copies relative to peptidylprolyl isomerase A (PPIA) ± S.E. (B) 17β-
HSD mRNA levels were determined relative to PPIA for individual patient samples using
quantitative PCR for androgen-stimulated benign prostate (AS-BP) (1–6 and 9), androgen-
stimulated prostate cancer (AS-CaP) (1 and 3–8), and castration-recurrent prostate cancer
(CR-CaP) (1–5).
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Table 1
Major enzymes of testosterone (T) and dihydrotestosterone (DHT) metabolism
Steroid conversion Enzyme activity Enzyme Acronym Reference
Androstenedione → T
Reductive 17β-HSD activity
17β-hydroxysteroid dehydrogenase (RED) 17β-HSD3, 17β-HSD5 25,28




steroid 5α-reductase type 1, 2 SRD5A1, SRD5A2 20
steroid 5α-reductase type 1, 2 SRD5A1, SRD5A2 26
DHT → Androstanediol
Reductive 3α-HSD activity
3α-hydroxysteroid dehydrogenase (RED) 3α-HSD 27
type 3 3α-HSD aldo-keto reductase 1C2 AKR1C2 19,30
Androstanediol → DHT Oxidative 3α-HSD activity
17β-hydroxysteroid dehydrogenase 6 17β-HSD6, RoDH-like 3α-HSD, RL-HSD
18,19
17β-hydroxysteroid dehydrogenase 10 17β-HSD10 54
retinol dehydrogenase 4 RoDH4 18
retinol dehydrogenase 5 RDH5, 11-cis-retinoldehydrogenase, RoDH5
18
dehydrogenase short-chain reductase family member
9 DHRS9, 3α-HSD
19,42
Androstanediol → Androsterone Oxidative 17β-HSD activity
17β-hydroxysteroid dehydrogenase 6 17β-HSD6 18,19
17β-hydroxysteroid dehydrogenase 11 17β-HSD11 55
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